Literature DB >> 34844000

Protocol for the models of primary osteoporosis screening in men (MOPS) cluster randomized trial.

Cathleen S Colón-Emeric1, Richard Lee2, Carl F Pieper3, Kenneth W Lyles2, Leah L Zullig2, Richard E Nelson4, Katina Robinson5, Ivuoma Igwe5, Jyotsna Jadhav5, Robert A Adler6.   

Abstract

Current guidelines recommend primary osteoporosis screening for at-risk men to reduce the morbidity, mortality, and cost associated with osteoporotic fractures. However, analyses in a national Veterans Health Administration cohort of over 4,000,000 men demonstrated that primary osteoporosis screening as it is currently operationalized does not benefit most older Veterans due to inefficient targeting and low subsequent treatment and adherence rates. The overall objective of this study is to determine whether a new model of primary osteoporosis screening reduces fracture risk compared to usual care. We are conducting a pragmatic group randomized trial of 38 primary care teams assigned to usual care or a Bone Health Service (BHS) screening model in which screening and adherence activities are managed by a centralized expert team. The study will: 1) compare the impact of the BHS model on patient-level outcomes strongly associated with fracture rates (eligible proportion screened, proportion meeting treatment criteria who receive osteoporosis medications, medication adherence, and femoral neck bone mineral density); 2) quantify the impact on provider and facility-level outcomes including change in DXA volume, change in metabolic bone disease clinic volume, and PACT provider time and satisfaction; and 3) estimate the impact on health system and policy outcomes using Markov models of screening program cost per quality adjusted life year based from health system and societal perspectives. Published by Elsevier Inc.

Entities:  

Keywords:  Cluster randomized trial; Osteoporosis; Screening

Mesh:

Substances:

Year:  2021        PMID: 34844000      PMCID: PMC9234902          DOI: 10.1016/j.cct.2021.106634

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.261


  62 in total

1.  Screening for osteoporosis.

Authors:  Diane Altkorn; Adam S Cifu
Journal:  JAMA       Date:  2015-04-14       Impact factor: 56.272

2.  Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold.

Authors:  Peter J Neumann; Joshua T Cohen; Milton C Weinstein
Journal:  N Engl J Med       Date:  2014-08-28       Impact factor: 91.245

3.  Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial.

Authors:  Lee Shepstone; Elizabeth Lenaghan; Cyrus Cooper; Shane Clarke; Rebekah Fong-Soe-Khioe; Richard Fordham; Neil Gittoes; Ian Harvey; Nick Harvey; Alison Heawood; Richard Holland; Amanda Howe; John Kanis; Tarnya Marshall; Terence O'Neill; Tim Peters; Niamh Redmond; David Torgerson; David Turner; Eugene McCloskey
Journal:  Lancet       Date:  2017-12-16       Impact factor: 79.321

4.  Limited Osteoporosis Screening Effectiveness Due to Low Treatment Rates in a National Sample of Older Men.

Authors:  Cathleen S Colón-Emeric; Carl F Pieper; Courtney H Van Houtven; Janet M Grubber; Kenneth W Lyles; Joanne Lafleur; Robert A Adler
Journal:  Mayo Clin Proc       Date:  2018-12       Impact factor: 7.616

5.  Meta-analysis: excess mortality after hip fracture among older women and men.

Authors:  Patrick Haentjens; Jay Magaziner; Cathleen S Colón-Emeric; Dirk Vanderschueren; Koen Milisen; Brigitte Velkeniers; Steven Boonen
Journal:  Ann Intern Med       Date:  2010-03-16       Impact factor: 25.391

6.  Mobility after hip fracture predicts health outcomes.

Authors:  K M Fox; W G Hawkes; J R Hebel; G Felsenthal; M Clark; S I Zimmerman; J E Kenzora; J Magaziner
Journal:  J Am Geriatr Soc       Date:  1998-02       Impact factor: 5.562

7.  Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.

Authors:  Eric S Orwoll; Paul D Miller; Jonathan D Adachi; Jacques Brown; Robert A Adler; David Kendler; Christina Bucci-Rechtweg; Aimee Readie; Peter Mesenbrink; Robert S Weinstein
Journal:  J Bone Miner Res       Date:  2010-10       Impact factor: 6.741

8.  Unifying screening processes within the PROSPR consortium: a conceptual model for breast, cervical, and colorectal cancer screening.

Authors:  Elisabeth F Beaber; Jane J Kim; Marilyn M Schapira; Anna N A Tosteson; Ann G Zauber; Ann M Geiger; Aruna Kamineni; Donald L Weaver; Jasmin A Tiro
Journal:  J Natl Cancer Inst       Date:  2015-05-07       Impact factor: 13.506

9.  Intraclass correlation coefficients typical of cluster-randomized studies: estimates from the Robert Wood Johnson Prescription for Health projects.

Authors:  David M Thompson; Douglas H Fernald; James W Mold
Journal:  Ann Fam Med       Date:  2012 May-Jun       Impact factor: 5.166

10.  Medication adherence: process for implementation.

Authors:  Phil Mendys; Leah L Zullig; Rebecca Burkholder; Bradi B Granger; Hayden B Bosworth
Journal:  Patient Prefer Adherence       Date:  2014-07-28       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.